TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

DAWNZERA (AUTOINJECTOR)

DONIDALORSEN SODIUM
Approved 2025-08-21
Jump to: Indications Approvals Trials Competitors Safety Patents
1
Indication
--
Phase 3 Trials
0
Years on Market

Details

Status
Prescription
First Approved
2025-08-21
Routes
SUBCUTANEOUS
Dosage Forms
SOLUTION

Companies

IONIS PHARMS INC
Active Ingredient: DONIDALORSEN SODIUM

DAWNZERA (AUTOINJECTOR) Approval History

Loading approval history...

What DAWNZERA (AUTOINJECTOR) Treats

1 FDA approvals

Originally approved for its first indication in 2025 .

  • Other (1)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DAWNZERA (AUTOINJECTOR) FDA Label Details

Pro

DAWNZERA (AUTOINJECTOR) Patents & Exclusivity

Latest Patent: Apr 2035

Patents (5 active)

US10294477 Expires May 1, 2035
US9670492 Expires Aug 28, 2034
US9127276 Expires May 1, 2034
US9181549 Expires May 1, 2034
US9315811 Expires Oct 21, 2032
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: NDA219407 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.